EPx4 Raises Odds of Renal, Nerve, Hearing Harms - Takeaways - MDSpire

EPx4 Raises Odds of Renal, Nerve, Hearing Harms

Multicenter outcomes study finds cisplatin dose drives toxicity differences between guideline-endorsed regimens, with kidney function decline predicting cardiovascular risk

  • By

  • Kerri Miller

  • February 25, 2026

  • 5 min

Share

  • 1

    Long-term survivors of testicular cancer treated with EPx4 face higher odds of renal impairment, ototoxicity, and peripheral neuropathy compared to BEPx3.

  • 2

    The study analyzed 798 patients who completed cisplatin-based chemotherapy, with a median follow-up age of 45 years and median time since treatment of 11 years.

  • 3

    Patients receiving EPx4 had 1.55 times the odds of renal impairment and 1.48 times the odds of hearing loss compared to those treated with BEPx3.

  • 4

    41% of patients exhibited reduced eGFR below 90 mL/min/1.73 m², exceeding US population norms, with significant associations to hypertension and cardiovascular disease.

  • 5

    Chemotherapy regimen significantly impacted self-reported global physical health, with BEPx4 and VIPx4 showing the most pronounced reductions in health scores.

Original Source(s)

EPx4 Raises Odds of Renal, Nerve, Hearing Harms

  • by Kerri Miller

  • February 25, 2026

Related Content

Ensitrelvir Reduced COVID After Household Exposure

In SCORPIO-PEP, symptomatic COVID-19 occurred in 3% vs 9% of household contacts by day 10.

Folate Biomarkers Linked to Lung Cancer

Cross-sectional NHANES analysis found associations between select folate markers and self-reported physician-diagnosed lung cancer, though the direction and clinical significance of the relationship remain unclear

Why FDA Said No to a Melanoma Drug

Questions over trial design and political pressure shadowed the rejection of Replimune’s RP1 treatment.